JP2017503756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503756A5 JP2017503756A5 JP2016533116A JP2016533116A JP2017503756A5 JP 2017503756 A5 JP2017503756 A5 JP 2017503756A5 JP 2016533116 A JP2016533116 A JP 2016533116A JP 2016533116 A JP2016533116 A JP 2016533116A JP 2017503756 A5 JP2017503756 A5 JP 2017503756A5
- Authority
- JP
- Japan
- Prior art keywords
- muscle activity
- treatment
- deuterium
- abnormal muscle
- structural formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907675P | 2013-11-22 | 2013-11-22 | |
| US61/907,675 | 2013-11-22 | ||
| PCT/US2014/066740 WO2015077520A1 (en) | 2013-11-22 | 2014-11-21 | Methods of treating abnormal muscular activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017503756A JP2017503756A (ja) | 2017-02-02 |
| JP2017503756A5 true JP2017503756A5 (enExample) | 2018-01-11 |
Family
ID=53180159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533116A Pending JP2017503756A (ja) | 2013-11-22 | 2014-11-21 | 異常な筋活動を処置する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160303110A1 (enExample) |
| EP (1) | EP3071565A4 (enExample) |
| JP (1) | JP2017503756A (enExample) |
| CA (1) | CA2930167A1 (enExample) |
| HK (1) | HK1224294A1 (enExample) |
| IL (1) | IL245538A0 (enExample) |
| MX (1) | MX2016006622A (enExample) |
| WO (1) | WO2015077520A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP4345100A3 (en) | 2012-09-18 | 2024-04-10 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| NZ720301A (en) | 2013-12-03 | 2022-01-28 | Auspex Pharmaceuticals Inc | Deuterated tetrabenazine compounds |
| EP2918266A1 (en) * | 2014-03-11 | 2015-09-16 | CDRD Berolina AB | Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease |
| IL305352A (en) | 2015-03-06 | 2023-10-01 | Auspex Pharmaceuticals Inc | Methods for treating abnormal movement disorders |
| US10047077B2 (en) | 2016-04-13 | 2018-08-14 | Skyline Antiinfectives, Inc. | Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams |
| US10786202B2 (en) | 2016-09-28 | 2020-09-29 | International Business Machines Corporation | Quantifying grip strength and characterizing movement idioms |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7367953B2 (en) * | 2003-11-26 | 2008-05-06 | Ge Medical Systems Global Technology Company | Method and system for determining a period of interest using multiple inputs |
| AU2007214622B2 (en) * | 2006-02-17 | 2012-02-23 | Teva Pharmaceuticals International Gmbh | Deuterated catecholamine derivatives and medicaments comprising said compounds |
| ES2525932T3 (es) * | 2006-05-02 | 2015-01-02 | The Trustees Of The University Of Pennsylvania | Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología |
| US7897768B2 (en) * | 2007-06-08 | 2011-03-01 | General Electric Company | Method for making tetrabenazine compounds |
| AU2009257201B2 (en) * | 2008-06-12 | 2015-04-02 | Global Kinetics Pty Ltd | Detection of hypokinetic and/or hyperkinetic states |
| WO2010002972A1 (en) * | 2008-07-01 | 2010-01-07 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| CA2736409C (en) * | 2008-09-18 | 2017-07-11 | Auspex Pharmaceutical, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| US20120003330A1 (en) * | 2010-06-01 | 2012-01-05 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012006551A2 (en) * | 2010-07-08 | 2012-01-12 | The Brigham And Women's Hospital, Inc. | Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules |
| EP3884937A1 (en) * | 2012-03-23 | 2021-09-29 | Cardero Therapeutics, Inc. | Compounds and compositions for the treatment of muscular disorders |
-
2014
- 2014-11-21 CA CA2930167A patent/CA2930167A1/en not_active Abandoned
- 2014-11-21 HK HK16112663.3A patent/HK1224294A1/zh unknown
- 2014-11-21 EP EP14864919.7A patent/EP3071565A4/en not_active Withdrawn
- 2014-11-21 WO PCT/US2014/066740 patent/WO2015077520A1/en not_active Ceased
- 2014-11-21 JP JP2016533116A patent/JP2017503756A/ja active Pending
- 2014-11-21 US US15/037,465 patent/US20160303110A1/en not_active Abandoned
- 2014-11-21 MX MX2016006622A patent/MX2016006622A/es unknown
-
2016
- 2016-05-08 IL IL245538A patent/IL245538A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503756A5 (enExample) | ||
| NZ721645A (en) | Compounds for use as gpr120 agonists | |
| RU2010145459A (ru) | Ингибиторы активности протеинтирозинкиназы | |
| JP2012526791A5 (enExample) | ||
| EA201590520A1 (ru) | Фармацевтическая композиция с покрытием, содержащая регорафениб | |
| CL2013001558A1 (es) | El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico. | |
| JOP20180113B1 (ar) | مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية | |
| FI3738434T3 (fi) | Välituotteita substituoitujen bentsaldehydiyhdisteiden saamiseksi ja menetelmiä niiden käyttöön kudosten hapetuksen lisäämiseksi | |
| HRP20191617T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| JP2015513557A5 (enExample) | ||
| MY189770A (en) | Biaryl derivative as gpr120 agonists | |
| BR112014005389A8 (pt) | Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal | |
| PE20160874A1 (es) | Compuestos quimicos | |
| WO2016012965A3 (en) | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof | |
| JP2013525444A5 (enExample) | ||
| RU2008139315A (ru) | Избирательные андрогенные рецепторные модуляторы | |
| EP2681236A4 (en) | METHOD FOR PRODUCING GUANYLATE CYCLASE C AGONISTS | |
| MX369956B (es) | Metodos para preparar compuestos de benzoquinolina. | |
| EA201071099A1 (ru) | СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR | |
| JP2014062126A5 (enExample) | ||
| EA201490269A1 (ru) | Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета | |
| BR112018006866A2 (pt) | compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos | |
| BR112022008786A2 (pt) | Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose | |
| JP2017511377A5 (enExample) | ||
| EA201200046A1 (ru) | Новые соединения, фармацевтическая композиция и связанные с ними способы |